That marks one more triumph for mankinds' ingenuity, and a comeback for Nature as well. The development of Prialt, which reached the market earlier this year, neatly demonstrates the latest twist in our relationship with the global ecosystem. As the flow of new drugs down the research pipeline slows to a trickle pharmaceutical companies are turning again to the natural world for inspiration. Researchers now talk of promising new drugs derived from a vast range of living organisms-everything from Brazilian snakes to Hawaiian mollusks. "The industry is in crisis," says Grahan Dutfield, an authority on the bioprospecting business at Queen Mary College in London. "The companies are throwing masses of money at research but just not getting the returns. That's why they are looking at different options.